asthma is one of the most common childhood chronic diseases worldwide. Subcutaneous immunotherapy (SciT) is commonly used in the treatment of house dust mite (HdM)-related asthma in children. However, the therapeutic mechanism of SciT in asthma remains unclear. The present study aimed to investigate the molecular biomarkers associated with HdM-related asthma in asthmatic children prior and subsequent to SciT treatment compared with those in healthy children via proteomic analysis. The study included a control group (30 healthy children),-Treatment group (30 children with HdM-related allergic asthma) and +Treatment group (30 children with HdM-related allergic asthma treated with SciT). an isobaric labeling with relative and absolute quantification-based method was used to analyze serum proteome changes to detect differentially expressed proteins, while functional enrichment and protein-protein interaction network analysis were used to select candidate biomarkers. a total of 72 differentially expressed proteins were detected in the-Treatment, +Treatment and control groups. a total of 33 and 57 differentially expressed proteins were observed in the-Treatment vs. control and +Treatment vs. control groups, respectively. Through bioinformatics analysis, 5 candidate proteins [keratin 1 (KRT1), apolipoprotein B (APOB), fibronectin 1, antithrombin iii (SerPinc1) and α-1-antitrypsin (SerPina1)] were selected for validation by western blotting; among them, 4 proteins (KrT1, aPoB, SerPinc1 and SerPina1) showed robust reproducibility in asthma and control samples. This study illustrated the changes in proteome regulation following SciT treatment for asthma. The 4 identified proteins may serve as potential biomarkers prior and subsequent to SciT treatment, and help elucidate the molecular regulation mechanisms of SciT to treat HdM-related asthma.